Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Malignant Melanoma (US)

Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these cancers includes therapies that target or inhibit certain proteins, including Merck & Co.’s Keytruda, Bristol Myers Squibb’s Opdivo, AstraZeneca’s Imjudo, and Pfizer’s Tukysa and Braftovi. Although biomarker-driven therapies offer the advantage of selecting the patients most likely to respond to targeted therapy, they are typically premium-priced and thus subject to payer restrictions and cost-containment strategies. Identifying the barriers that influence the coverage and uptake of biomarker-driven therapies is key to a successful market strategy.

QUESTIONS ANSWERED

• What factors most influence payers’ reimbursement decisions about biomarker-driven therapies for NSCLC, colorectal cancer, and malignant melanoma?

• Do access and reimbursement challenges differ by indication, and how well established are biomarkers in each indication?

• Which payer-imposed utilization management controls most restrict oncologists’ prescribing of biomarker-driven therapies?

• What are payers’ opinion of emerging agents, and how will oncologists’ prescribing patterns change with the launch of new therapies?

• What factors influence reimbursement and access to companion biomarker tests?

PRODUCT DESCRIPTION

Leveraging Clarivate’s proprietary data sources and surveys with physicians and payers, Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:

• Identify and learn how to overcome roadblocks to market access to best position your brand.
• Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.
• Evaluate competitor strategies for securing favorable market access terms.

Markets covered: United States

Key drugs: Keytruda, Opdivo, Libtayo, Tecentriq, Tukysa, Imfinzi, Imjudo, Fruzaqla, Braftovi